A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Forskningsoutput: TidskriftsbidragPublicerat konferensabstract

Bibtex

@article{e53174a6c67343f29c01797a8966fc76,
title = "A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer",
author = "S Margolin and L Carlsson and M Hellstr{\"o}m and P Karlsson and E Lidbrink and B Linderholm and H Lindman and Per Malmstr{\"o}m and {Sk{\"o}ld Pettersson}, D and J Bergh",
year = "2008",
doi = "10.1016/S1359-6349(08)70548-2",
language = "English",
volume = "6",
pages = "116--117",
journal = "European Journal of Cancer Supplements",
issn = "1359-6349",
publisher = "Elsevier",
number = "7",
note = "EBCC-6, European Breast Cancer Conference, 2008 ; Conference date: 14-04-2008 Through 19-04-2008",

}